Eric Crombez - 01 Mar 2026 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: EVP and Chief Medical Officer
Signature: /s/ Karah Parschauer, attorney-in-fact
Issuer symbol: RARE
Transactions as of: 01 Mar 2026
Net transactions value: -$160,261
Form type: 4
Filing time: 03 Mar 2026, 18:49:45 UTC
Previous filing: 02 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Crombez Eric	EVP and Chief Medical Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO	/s/ Karah Parschauer, attorney-in-fact	03 Mar 2026	0001653052

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Award	$0	+11,643	+16%	$0.000000	83,173	01 Mar 2026	Direct	F1
transaction	RARE	Common Stock	Sale	$160,261	-7,029	-8.4%	$22.80	76,301	02 Mar 2026	Direct	F2, F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics.
F2	Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
F4	Includes 157 shares acquired on October 30, 2025 under the Company's Amended and Restated Employee Stock Purchase Plan
F5	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.